Member Info for Alwaysone

I totallly agree with your comment on ARM.
I lost a fair bit many years ago when ARM had a profit warnng back at 90p ( I bough tthe day before). I had to close my trade due to the T20 and lack of cash back then. But the price and swings if ignored and just held, well you know where it ended up!

Can't get a live quote

Going through .40p with ease it seems
Should easily smash the all time high after this news

· Under the Kodal Subscription, the Hainan Group is conditionally subscribing for 2,937,801,971 ordinary shares in Kodal (the "Kodal Subscription Shares") for a total subscription amount of US$17.75 million (£14.6 million), equating to a subscription price of 0.5p per share, being a premium of approximately 100% to the previous 10-days' VWAP (volume weighted average share price).

Doesn't take many trades to move this one up, or down.

21% up in a month, and I didn't do RR as I thought it would be too slow to rise and boring. How wrong I was here! Must be a good long term hold here also.. I'll wait for any dips....

Does seem a screamign buy now
https://www.asktraders.com/analysis/why-avacta-shares-have-risen-11-8-in-the-first-week-of-2023/
The company’s most promising drug candidate is AAV6000, its patented pro-doxorubicin (AVA6000) treatment for cancerous tumours. It is in phase I clinical trials and is set to release the final results from the clinical trial this year.
AVA6000 is a promising chemotherapy treatment that seeks to improve the absorption and dosage of doxorubicin in cancer patients by eliminating some of its harmful side effects, including damaging healthy tissues around the heart.

The drug delivered positive safety data early in the phase 1 clinical trial. Avacta is already dosing participants with more than double the typical dosage of doxorubicin at 200mg/m2.

The company’s Affirmer platform is an innovative alternative to antibodies derived from a small human protein. The platform addresses many negative issues associated with antibodies and has a total addressable market of over $100 billion.

Avacta’s pre|CISION platform is designed to release active chemotherapy selectively in FAP-rich tumour tissues to limit the systemic exposure that causes damage to healthy tissues. It aims to improve powerful anti-cancer treatments’ overall safety and therapeutic potential.

AVA6000 is based on the pre|CISION platform, whose wider applications have a total addressable market expected to reach $56 billion in 2024. The company’s drugs and drug discovery platforms have significant revenue potential.

Therefore, Avacta shares could rally higher upon the release of the AVA6000 final phase 1 clinical data if it is positive. The company has also licensed some drug candidates and technologies to other firms, such as Daewoong Pharma and LG Chem.
Analysts at Trinity Delta have a price target of 219p on Avacta shares, but some think the target is relatively low if the company can achieve even half its full potential. xxxxxxxxxxxxx

Agree that it does seemea Re rate has started - great two days playing catch up

Great time to buy imho. Just bought in

Some movement up at long last!

DARK had no effect here then, which I thought it might do

Taken off again after the midday profit takers.

Final top up at £3.44 this morning, fully locked and loaded

The share price has improved a lot since Lemos took over. Market seems to have great confidence in him

Yes, very frustating. PXC well up again....

Seems odd that people didnt take up the 4p options when the share price is a lot higher, or am I missing something?
7,818,750 at 4p expired 19th Nov 2022 have now lapsed.

This one just doesn't stop giving. The company I work for has traded with MM for 10 years and I still missed the boat here!!

Great news!

Who knows.............

There will be a large option seller to accomodate these is my guess, like yesterday, let's see